Ozempic Alternatives in the Philippines

On 13 June 2026 Manila Bulletin published a report titled "Ozempic: soaring prices, shrinking stock of Philippines' most wanted injection". It is the clearest published account of what has happened to this drug in the Philippine market, and it explains most of the search traffic that lands on a page like this one.

The reported price arc is stark. Patients who started three years ago were paying about ₱6,200 to ₱6,300 a pen. By May 2026 major drugstores were listing the 1mg dose at ₱8,734, and a pharmacy in Las Piñas was quoted at ₱11,368 for the same pen. That is verifiable against the current Watsons Philippines listing, which shows ₱7,650 for the 0.25mg and 0.5mg pens and ₱8,734 for the 1mg pen, all prescription-required and restricted to Click and Collect or express delivery.

The supply side is worse than the price side. A pharmacist at a Baliuag branch described being directed by management to start rationing, with patients capped at two pens per dosage per month. One patient described having stock shipped from Mindanao to Metro Manila simply to fill a prescription. The root cause is a global manufacturing bottleneck that began in 2022, driven by off-label weight-loss demand landing on a supply chain built for diabetes volumes.

The demand context in this country is large enough that nobody should expect this to resolve quietly. The same report cited roughly 4.7 million Filipino adults living with diabetes, diabetes as the fifth leading cause of death in 2025 at 27,516 recorded cases, and around 27 million Filipinos classified as overweight or obese. It also noted that Philippine FDA registration for Ozempic is for type 2 diabetes management, and that the Philippine College of Endocrinology had warned in August 2025 against compounded formulations circulating online.

This is the centrepiece of the page. Everything below is a product you can obtain in the Philippines, ordered cheapest first by realistic monthly cost. Read the right-hand column before the middle one, because the caveat is what makes the number meaningful.

Basis for the arithmetic. Metformin: RiteMed 500mg at ₱4.25 a tablet on Watsons Philippines, two tablets daily. Orlistat: Watsons Generics 120mg at ₱24.68 a capsule and Xenical at ₱51.25 a capsule, three capsules daily. Trulicity: Southstar Drug listing at ₱1,766.25 a 1.5mg pen, four weekly pens. Ozempic, Wegovy, Saxenda and Mounjaro: Watsons Philippines brand listings. Saxenda is calculated at 3.0mg daily from an 18mg pen, which is about six days a pen. Research-grade figure is the Primara Labs tirzepatide 15mg vial price.

Mounjaro, tirzepatide. The strongest like-for-like case on the list, and the most expensive. It is a weekly injection acting on both GIP and GLP-1 receptors, sold in a KwikPen holding four weekly doses, at ₱11,650 for the 2.5mg starter through to ₱29,900 at 15mg on the Watsons listing. It is a prescription medicine and it has its own supply problems. Full detail in the Mounjaro price and access filing.

Wegovy, semaglutide. The same molecule as Ozempic at a weight-management label and a higher price. Watsons lists the 0.25mg, 0.5mg and 1mg pens at ₱9,900, the 1.7mg at ₱11,600 and the 2.4mg at ₱12,650. The FlexTouch pen carries four weekly doses, so a pen is roughly a month. If your reason for leaving Ozempic is cost or supply, Wegovy does not solve either, because it is the same manufacturer drawing on the same molecule. The Wegovy price filing and the Wegovy versus Ozempic comparison cover the label difference.

Saxenda, liraglutide. The most commonly misread price on this page. Watsons lists a pen at ₱3,381, discounted to ₱2,366.70, which makes it look like the cheap option. It is a daily injection and the pen holds 18mg. At the 3.0mg maintenance dose that is six days a pen, so roughly five pens a month and a real cost of about ₱11,800 to ₱16,900. At the 0.6mg starting dose a pen lasts a month, which is where the misleading comparison comes from. Details in the Saxenda filing.

Trulicity, dulaglutide. Registered in the Philippines for type 2 diabetes. Weight use is off-label and should be named as such in any conversation with a prescriber. Southstar Drug lists the 1.5mg pre-filled pen at ₱1,766.25, and it is a weekly injection, so four pens is a month at roughly ₱7,065. That is the cheapest weekly GLP-1 injection with a published Philippine price on this list. Stock is the constraint: the listing was showing available soon rather than in stock at the time of reading.

Rybelsus, oral semaglutide. The same molecule as Ozempic in a once-daily tablet. It is a prescription medicine here and stock is thinner than the injectable. No Philippine retail chain publishes a current price for it that stands up to checking, so this page does not print one. What can be said is that branch quotes land in five-figure monthly territory and do not meaningfully undercut the pens. Anyone offering a dramatically cheaper Rybelsus is worth a hard question. The oral semaglutide filing covers the tablet route properly.

Orlistat. Registered and genuinely on the shelf. Xenical 120mg is ₱51.25 a capsule at Watsons, which is about ₱4,610 a month at three capsules daily with meals. Watsons Generics orlistat 120mg is ₱24.68 a capsule, roughly ₱2,220 a month, and it is the same molecule. Alli, the 60mg over-the-counter version sold in other markets, is not registered in the Philippines. Orlistat works on fat absorption rather than appetite, the effect size in trials is modest, and the gastrointestinal side effects are the main reason people stop.

Duromine, phentermine. FDA Philippines registered in 15mg and 30mg under registration DR-XY26998, and prescription only. It is a short-term appetite suppressant of an entirely different class, not a GLP-1, and it is not a substitute for one. No major Philippine pharmacy chain publishes a retail price, and most of what surfaces in a search is classified listings and marketplace sellers. Those are not a channel worth using for a prescription-only stimulant. The Duromine filing goes through why.

Metformin, off-label. Registered, cheap and everywhere. RiteMed 500mg is ₱4.25 a tablet at Watsons and requires a prescription, so two tablets daily is about ₱255 a month. It is widely used off-label for weight, and it is honest to say that its weight effect is a fraction of what a GLP-1 does. It belongs on this list because it is a real registered option that a prescriber may raise, not because it replaces semaglutide.

A broader look at the oral category, including the products that do not work, sits in the diet pills filing. Contrave, which people ask about, shows no evidence of Philippine registration.

A large share of the people searching for an Ozempic alternative in this country end up looking at research-grade peptide vials, so this page would be incomplete without addressing them. The important thing to be clear about is that they are not a cheaper version of a pharmacy product. They are a different category with a different legal status.

Research compounds such as tirzepatide, semaglutide and retatrutide are supplied as lyophilized powder in vials for laboratory research. They are not registered with FDA Philippines and are not approved for human therapeutic use in this country. There is no prescription, no pharmacy cold chain that a regulator audits, and no recourse if something is wrong. That is the trade, stated plainly, and it is a materially different set of risks from a pen bought at a Watsons counter against a script.

The price gap is what draws attention. A 10mg research vial at ₱1,990 works outto ₱199 a milligram against roughly ₱498 to ₱1,165 a milligram for branded tirzepatide in a KwikPen. That is a real arithmetic difference and it is also not a comparison between two versions of the same purchase.

Sourcing risk in this category is not abstract in the Philippines. The NBI arrested two people in Tondo, Manila on 13 May 2026 for selling unregistered tirzepatide online, seizing about ₱310,000 in product, with the case built on RA 9711 section 10(j) alongside RA 10175 and RA 7394. On 27 May 2026 the NBI and FDA raided an aesthetic clinic in Pasig over unregistered whitening and slimming injectables. The legality filing sets out the regulatory frame, and the weight-loss peptides filing covers the compounds themselves.

Cost tables invite bad substitutions, so here is the plain version. This is not a recommendation to make any of these switches. It is a statement of which conversations with a prescriber are coherent and which are not.

The pattern is straightforward once you see it. Within the GLP-1 and incretin class there are genuine alternatives, and the trade is between price, availability, dosing frequency and label. Outside that class there are cheaper products, and the trade is a much smaller expected effect. Nothing on the Philippine market gives you GLP-1 class results at orlistat prices, and any page or seller implying otherwise is selling you something.

Marketplace and social sellers. Shopee, Lazada reseller pages, Facebook groups and Viber sellers are the documented informal channel for GLP-1 pens in this region, and a shortage is exactly the condition under which counterfeits move. A labelled box tells you nothing about contents, batch or storage history. The counterfeit filing documents what has actually turned up here.

Compounded formulations. The Philippine College of Endocrinology issued a warning in August 2025 against compounded GLP-1 formulations circulating online. A compounded product is not a registered medicine and does not carry the manufacturing controls of one, however clinical the website presenting it looks.

Slimming injections at aesthetic clinics. A category worth naming because the enforcement record here is specific. The NBI and FDA raided a Pasig aesthetic clinic on 27 May 2026 over unregistered whitening and slimming injectables. If a clinic will not tell you the molecule, the manufacturer and the registration status of what is in the syringe, that is the answer. See the slimming injections filing.

Fat burner supplements. Widely sold, cheap enough to feel harmless, and the worst value on the shelf. A supplement at ₱1,500 a month for a year is ₱18,000 spent on something with no comparable evidence base behind it. That is more than a month of Mounjaro.

Everything registered on this page requires a prescription in the Philippines, and that is not an obstacle to be routed around. It is the mechanism that makes the product traceable. The useful move is to arrive at the consultation with the cost picture already in hand, so the conversation can be about what fits you rather than about what you can find.

Four things worth bringing to that appointment:

• Your actual budget per month, stated as a number, because it changes which options are worth discussing at all.
• Whether you can commit to a daily injection or need a weekly one, since that alone rules several rows in or out.
• Which branches near you have stock right now, asked by strength and by milligram rather than by brand name.
• An explicit question about which options would be on-label and which would be off-label for you specifically.

For the wider price picture across the whole class, the GLP-1 price index is updated more often than this page, and the GLP-1 overview covers how the class works.